Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Biomea Fusion, Inc.
organization2 mentionslast seen Oct 14, 2026
Biopharmaceutical company developing GLP-131 for obesity treatment.
Relationships 7
- Biomea Fusion, Inc.developsBMF-65099% confidence2 sources
- Biomea Fusion, Inc.employsMick Hitchcock98% confidence1 source
- Biomea Fusion, Inc.employsThorsten Kirschberg98% confidence1 source
- Biomea Fusion, Inc.employsRamses Erdtmann98% confidence1 source
- Biomea Fusion, Inc.employsJuan Pablo Frías97% confidence1 source
- Biomea Fusion, Inc.employsMichael J.M. Hitchcock95% confidence1 source
- Biomea Fusion, Inc.developsicovamenib95% confidence1 source
Relationship
Biomea Fusion, Inc.developsBMF-650
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 13, 2026Biomea Fusion, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist
- filingSEC EDGARSep 22, 2026Biomea Fusion, Inc. 8-K: Item 8.01: Other Events
Biomea Fusion, Inc. (the "Company") updated the anticipated timing for topline results from the Company's ongoing Phase I GLP-131 trial for BMF-650